NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD
Taking everything into account, NTLA scores 3 out of 10 in our fundamental rating. NTLA was compared to 561 industry peers in the Biotechnology industry. The financial health of NTLA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NTLA is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -53.33% | ||
ROE | -67.43% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.71 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.9 | ||
Quick Ratio | 4.9 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
9.2
-0.47 (-4.86%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 20.9 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.22 | ||
P/tB | 1.22 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -53.33% | ||
ROE | -67.43% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 39.01% | ||
Cap/Sales | 8.79% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.9 | ||
Quick Ratio | 4.9 | ||
Altman-Z | -1.71 |